Transoral Robotic Surgery and Adjuvant Therapy for Oropharyngeal Carcinomas and the Influence of p16 INK4a on Treatment Outcomes
|
|
- Maud Thornton
- 5 years ago
- Views:
Transcription
1 The Laryngoscope VC 2013 The American Laryngological, Rhinological and Otological Society, Inc. Transoral Robotic Surgery and Adjuvant Therapy for Oropharyngeal Carcinomas and the Influence of p16 INK4a on Treatment Outcomes Harry Quon, MD; Marc A. Cohen, MD; Kathleen T. Montone, MD; Amy F. Ziober, JD; Li Ping Wang, MD; Gregory S. Weinstein, MD; Bert W. O Malley, Jr., MD Objectives/Hypothesis: To determine the prognostic influence of p16 INK4a immunohistochemistry on the survival of resectable oropharyngeal carcinomas (OPSCC). Study Design: Retrospective pathologic evaluation of a prospective single-arm cohort study at a tertiary referral center. Methods: There were 48 patients with resectable OPSCC who consented for transoral robotic surgery (TORS) and banked tissue specimen for assessment. TORS was with or without adjuvant radiation or chemoradiation. Main outcome measures were p16 INK4a status, human papillomavirus status, local-regional disease control, and overall, disease-specific, and disease-free survival. Results: p16 INK4a and HPV positivity were identified in 73% and 74% of patients respectively. With a median follow-up of 38.8 months ( months), only one local-regional relapse has occurred in both the p16 INK4a -positive and p16 INK4a - negative cohorts. No disease-specific, disease-free, and overall survival differences were observed between p16 INK4a -positive and p16 INK4a -negative patients (P ¼.446, P ¼.277, P ¼.643, respectively). Conclusions: p16 INK4a was not prognostic in resectable OPSCC when treated with an initial TORS approach. Key Words: p16 INK4a, prognosis, oropharyngeal carcinoma, human papilloma virus, transoral robotic surgery. Level of Evidence: 2b. Laryngoscope, 123: , 2013 INTRODUCTION A significant advancement in the management of oropharyngeal squamous cell carcinomas has been the consistent demonstration that human papillomavirus (HPV)-associated oropharyngeal carcinomas (HPV- OPSCC) have a favorable prognosis. 1,2 This appears to be independent of the treatment approach, be it radiation therapy, 3 chemoradiation, 2,4 or surgery. 5 The mechanism for this is unclear, but evidence suggests that the favorable prognosis may in part be dependent on an intact and functional p16 INK4a protein expression. 5,6 Recently, our group demonstrated that the survival outcome for HPV-negative OPSCC when treated surgically with the transoral robotic surgical (TORS) technique was not statistically different from HPV-positive OPSCC. 7 This observation is contrary to other reports where From the Department of Radiation Oncology (H.Q.), Department of Pathology and Laboratory Medicine (K.T.M., A.F.Z., L.P.W.), Department of Otorhinolaryngology Head and Neck Surgery (H.Q., M.A.C., G.S.W., B.W.O.), Abramson Cancer Center (H.Q., K.T.M., G.S.W., B.W.O.), University of Pennsylvania (H.Q., K.T.M., G.S.W., B.W.O.), Philadelphia, Pennsylvania, U.S.A. Editor s Note: This Manuscript was accepted for publication April 18, The authors have no funding, financial relationships, or conflicts of interest to disclose. Harry Quon, MD, Gregory S. Weinstein, MD, and Bert W. O Malley, Jr., MD, contributed equally to this work as first authors. Send correspondence to Harry Quon, MD, MS, Johns Hopkins University, Department of Radiation Oncology and Molecular Radiation Sciences, 410 North Broadway, Suite 1440, Baltimore, MD hquon2@jhmi.edu DOI: /lary OPSCC and head and neck squamous cell carcinoma (HNSCC) have been treated nonsurgically. 2 As daily fractionated radiotherapy is an oxygen-dependent process for there to be effective local-regional control (LRC) of HNSCC, 8 we hypothesized that the absence of survival difference between HPV-positive and HPV-negative OPSCC may be attributed to the beneficial effects of adding TORS surgery in combination with radiation and chemotherapy as pathologically indicated. As such, we sought to analyze the outcomes of p16 INK4a -positive and p16 INK4a -negative OPSCC patients treated with an upfront TORS approach. MATERIALS AND METHODS Patients analyzed were prospectively enrolled on a clinical trial evaluating the safety and efficacy of TORS. The primary aim of this study was to evaluate the influence of p16 INK4a in newly diagnosed oropharyngeal carcinomas treated initially with TORS. The outcome data for this trial was collected prospectively from a pool of 162 patients enrolled in a phase I protocol approved by the institutional review board at the Hospital of the University of Pennsylvania (Philadelphia, PA). The inclusion and exclusion criteria have previously been reported. 9 Of the 162 patients enrolled in the TORS protocol, nine patients did not receive surgery at all. Of the 153 patients receiving some type of surgery, three patients were excluded from TORS during a preoperative endoscopy that demonstrated that exposure for TORS was suboptimal. Of these final 150 patients who received TORS, there were 79 patients identified with previously untreated, biopsy-proven, squamous cell carcinoma of the oropharynx. Of these 79 patients, there were tumor-banked specimens for 48 patients for p16 INK4a 635
2 Patient Characteristics TABLE I. Summary of Patient Characteristics. No. of Patients (N¼48) T T N N Adjuvant radiotherapy, no (%) 12 (25) Adjuvant chemoradiotherapy, no (%) 25 (52 HPV positive:hpv negative, no (%) 37 (74):13 (26) p16 INK4a positive:p16 INK4a negative, no (%) 35 (73):13 (27) HPV positive/p16 INK4a positive, no (%) 32 (66) HPV positive/p16 INK4a negative, no (%) 4 (8) HPV negative/p16 INK4a positive, no (%) 3 (6) HPV negative/p16 INK4a negative, no (%) 9 (19) HPV ¼ human papillomavirus. assessment. These patients underwent TORS from May 24, 2005 to November 5, Clinical data, including age, gender, tumor, and American Joint Committee on Cancer stage, histopathological findings, resection margins, recurrence, speech and swallowing outcomes, and mortality were obtained prospectively with the last data collection performed in February The procedures for TORS of the oropharynx have been described in detail previously. 10,11 The surgical sites of 47 of the 48 patients were allowed to heal by secondary intention, with one early patient undergoing free tissue transfer. TORS was performed with the da Vinci surgical system (Intuitive Surgical, Inc., Sunnyvale, CA) in all cases. A thorough description of the pathologic assessment of tumor specimens has been described previously. 11 The indications for adjuvant therapy with intensity modulated radiation therapy with or without concurrent cisplatin have been described previously. 11 Briefly, indications for postoperative concurrent chemotherapy (typically, cisplatin) included the presence of nodal extracapsular extension and/or positive surgical margins. Relative indications for concurrent chemotherapy included multiple positive lymph nodes. Absolute indications for postoperative radiation without chemotherapy included the presence of two or more positive lymph nodes or positive surgical margins. We defined close or positive margins at the University of Pennsylvania as <2 mm. Relative indications for adjuvant radiation included T4 lesions with infiltrative growth patterns, perineural invasion, lymphovascular invasion, and the presence of one pathologically positive lymph node. In the early years as experience with the TORS technique was developing, there was a tendency to favor postoperative radiotherapy due to the uncertain negative predictive value of a negative margin (designated as 2 mm or greater) when evaluating a new surgical technique. p16 INK4a Immunohistochemistry Paraffin-embedded formalin-fixed tissue specimens of the primary oropharyngeal tumor were available for analysis. A total of 48 patients had sufficient material for analysis. There were 5-lm sections of formalin-fixed and paraffin-embedded biopsy samples processed by the CINtec Histology Kit (MTM Laboratories, Inc., Westborough, MA). Sections were de-waxed by passage through xylene and rehydrated by a graded series of ethanol, followed by boiling in 10 mmol/l of citrate buffer (ph 6.0) for 15 minutes. Endogenous peroxidase was inactivated by 3% H 2 O 2 in phosphate-buffered saline (PBS) (ph 7.4) for 10 minutes. After rinsing with PBS, sections were incubated at room temperature for 45 minutes with anti-p16 INK4a mouse monoclonal antibody (clone E6H4 TM ; MTM Laboratories, Inc.). After rinsing thoroughly with PBS, the slides were incubated with Visualization Reagent (MTM Laboratories, Inc.) for 30 minutes. After washing with PBS, visualization was performed with diaminobenzidine tetrahydrochloride (MTM Laboratories, Inc.), and sections were counterstained with hematoxylin. Strong nuclear staining as well as strong cytoplasmic staining were considered positive for p16 INK4a expression. Immunostaining was graded and scored on whole sections according to Klaes et al. 12 as follows: negative (<1% of the cells were positive), sporadic (isolated cells were positive, but <5%), focal (small cell clusters, but <25% of the cells were positive), and diffuse positive (>25% of the cells were stained). For survival analyses, immunoreactivity of >25% of the tumor cells were scored as p16 INK4a positive, <75% as p16 INK4a negative. HPV Polymerase Chain Reaction HPV type was assessed with the AttoSense HPV test (Sensi- Gen, Ann Arbor, MI) in an identifier blinded fashion by Sensigen. The AttoSense HPV test is a commercially available assay that uses a competitive real-time quantitative polymerase chain reaction technique in addition to flight mass spectroscopy, the details of which have been previously published. 13 Primers for serotype specific E6 allowed for detection of high-risk HPV types. These include HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and Standards allowed for quantification of each individual HPV serotype copies per cellular genome copy, and 10% percent of all samples were tested in duplicate to assure accuracy. Statistical Analysis Statistical analyses were computed using Statistical Package for Social Sciences version 17.0 (SPSS, Inc., Chicago, IL). Nonparametric statistics were performed using Pearson s v 2 and the Fisher exact test. Overall survival was defined as the time from TORS to the date of death. Disease-specific survival was defined as the time from TORS to the date of death secondary to OPSCC. Death without evidence of disease involved censorship at the patient s date of death. Disease-free survival (DFS) was defined as the time from TORS until disease recurrence or the date of death. Patients who were lost to follow-up were censored as per the disease status at the last clinic visit. Two patients total were lost to follow-up prior to 18 months follow-up with phone number changed and no response to letters. These two patients were p16ink4a-negative patients, one lost at 2.5 months without evidence of disease and one at 6.0 months following regional and distant disease recurrence. At last contact with the patient with disease recurrence, the patient was living with disease. The Kaplan-Meier method was used for analysis of survival data, and survival plots were compared using the logrank test. All statistics were two-tailed, and items were considered statistically significant with a P value <.05. RESULTS Patients analyzed were accrued and treated with TORS and adjuvant therapy as pathologically indicated from May 24, 2005 to November 5, Patient characteristics are summarized in Tables I and II. The majority of the patients were both HPV positive and p16 INK4a positive. Only 6% were HPV negative but p16 INK4a positive that would be expected to favorably influence the outcome of the HPV-negative cohort. There was a high degree of 636
3 TABLE II. Summary of T and N Stages for Patients by p16 INK4a Status. T1 T2 T3 T4 Total (%) p16 INK4a negative N (31) N (31) N (38) Total (%) 6 (46) 5 (39) 0 (0) 2 (15) 13 p16 INK4a positive N (14) N (46) N (40) Total (%) 8 (23) 18 (51) 8 (23) 1 (3) 35 concordance between the HPV and p16 INK4a status in 85% of the patients. Adjuvant therapy was administered in 85.7% of p16 INK4a -positive and 69.2% in p16 INK4a -negative patients. Of these, concurrent chemoradiotherapy was administered in 51.4% and 53.8%, respectively. Positive surgical margins were seen in 0% of p16 INK4a -positive and 7.7% in p16 INK4a -negative patients. The survival outcomes by HPV status have been previously been reported. 7 Table II summarizes the T and N stage by p16 INK4a status. Although there was more T1 disease (46% vs. 23%) and combined more T1 and T2 disease (85% vs. 74%) in the p16 INK4a -negative cohort compared to the p16 INK4a -positive cohort, there was comparable N2 disease in both study cohorts. Comparisons between the p16 INK4a -negative and the p16 INK4a -positive cohorts demonstrated a trend toward higher T-stages in the p16 INK4a -positive cohort (P ¼.06). Comparisons of nodal stages revealed a nonsignificant difference between the two p16 INK4a cohorts (P ¼.389). With a median follow-up of 38.8 months (mean, 36.5 months; range, months), only one local-regional relapse has occurred in both the p16 INK4a -positive and p16 INK4a -negative cohorts. As such, Figure 1, which demonstrates the overall actuarial local-regional disease control rates, was not separated by p16 INK4a status. Fig. 2. Actuarial disease-specific survival by p16ink4a status. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.] Figure 2 demonstrates the actuarial disease-specific survival rates by p16 INK4a status. No survival differences were observed (P ¼.446). The relapse pattern is summarized in Table III, which demonstrates that distant relapses appear to be the dominant pattern of relapse. Figure 3 demonstrates the actuarial DFS rates by p16 INK4a status. No significant differences were observed (P ¼.277). The DFS rate for the p16 INK4a -negative cohort was influenced by one patient with relapse (Table III), who died from other causes following successful surgical salvage, and two patients who died due to other causes. Figure 4 demonstrates the overall survival rates. This also demonstrated no statistically significant difference between the p16 INK4a -positive and p16 INK4a -negative cohorts (P ¼.643). When analyzed by both HPV and p16 INK4a status, the survival analysis is limited by the small patient numbers for the HPV-positive/p16 INK4a -negative and HPV-negative/p16 INK4a -positive cohorts. All patients in these discordant cohorts are free of recurrent disease. DISCUSSION The results reported suggest that p16 INK4a may not have a significant influence on the treatment outcomes of HPV-OPSCC when treated with an initial surgical approach using the TORS technique followed by adjuvant radiotherapy as pathologically indicated. Cohen TABLE III. Summary of Relapse Patterns by p16 INK4a Status. Fig. 1. Actuarial local-regional disease control rates. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.] Relapse Pattern No. of p16 INK4a - Positive Patients No. of p16 INK4a - Negative Patients Local alone 0 0 Regional alone 0 0 Local and regional 1 0 Regional and distant relapse 0 1 Distant relapse alone
4 Fig. 3. Actuarial disease-free survival by p16ink4a status. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.] Fig. 4. Actuarial overall survival by p16ink4a status. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.] Reference TABLE IV. Summary of Prognostic Studies for Survival of p16 INK4a Protein Expression Evaluated by Immunohistochemistry. p16 INK4a Prognostic Significance HPV Prognostic Significance Patient Population p16 INK4a -Monoclonal Antibody p16 INK4a -Positive Definition Primary surgical therapy Licitra et al. 5 Negative Positive Oropharynx NS* NS Fischer et al. 20 Positive NA All sites E6h4 a Rich et al. 21 Positive Negative Oropharynx NS b Klussman et al. 19 Positive NA Oropharynx 16p04 and 16p07* c Current series Negative Negative Oropharynx E6h4 d Primary radiation therapy Lassen et al. 3,17 Positive NA All sites JC8 e Rischin et al. 18 Positive NA Oropharynx NS* f Kumar et al. 22 Positive Positive Oropharynx 16p04 k g Higuchi et al. 23 Positive NA All sites Ab-7* h Shi et al. 24 Positive Positive Oropharynx E6h4 i Fischer et al. 20 Positive NA All sites E6h4 a Mixture of treatment approaches Smith et al. 6 Positive Positive All sites E6h4 j Li et al. 25 Positive Positive Oropharynx Ab-4/16p04 clone* k HPV ¼ human papillomavirus; NS ¼ not specified; NA ¼ not available; a ¼ nuclear accounting only for the proportion of cells and not staining intensity with <5% staining negative and >5% staining positive; b ¼ intracellular location not specified accounting only for the proportion of cells and not staining intensity with no staining negative and >75% staining positive; c ¼ nuclear and cytoplasmic with semiquantitative scores accounting only for the proportion of cells and not staining intensity: <25% staining negative and >25% staining positive; d ¼ nuclear and cytoplasmic with semiquantitative scores accounting only for the proportion of cells and not staining intensity: <25% staining negative and >25% staining positive; e ¼ nuclear and cytoplasmic with semiquantitative scores accounting only for the proportion of cells and not staining intensity: <10% staining negative and >10% staining positive; f ¼ nuclear and cytoplasmic with semiquantitative scores accounting only for the staining intensity: 0 (none), 1 (weak), 2 (moderate), or 3 (strong), with 0 or 1 scores defined as negative and 2 or 3 defined as positive; g ¼ intracellular location not specified accounting only for the proportion of cells and not staining intensity: 1 was <5%, 2 was 5% to 20%, 3 was 21% to 50%, and 4 was 51% to 100% tumor staining with definition of p16 positivity not specified; h ¼ nuclear staining accounting only for the proportion of cells staining with >1% staining positive; i ¼ nuclear and cytoplasmic with positivity defined as staining observed in both the nucleus and cytoplasm; j ¼ nuclear and cytoplasmic with semiquantitative scores accounting only for the proportion of cells and not staining intensity: 1 is negative for staining, 2 is slightly positive for staining, 3 is 10% to 80% positive, 4 is >80% positive; 5 is every tumor cell positive (slides in category 1 were defined as negative and 2 to 5 were positive; k ¼ intracellular location not specified accounting only for the proportion of cells and not staining intensity with <5% staining negative and >5% staining positive. *Neomarkers, Fremont, CA. MTM Laboratories AG, Heidelberg, Germany. MTM Laboratories CINtec, Westborough, MA. Santa Cruz Biotechnology, Inc., Santa Cruz, CA. k Lab-Vision, Fremont, CA. 80% of treated patients received radiotherapy. 638
5 et al. had reported similar nonsignificant results seen when analyzed by HPV status. 7 As Smith et al. have recently observed that p16 INK4a protein expression could influence the survival outcome of HPV-positive HNSCC patients, 6 we had speculated if the favorable survival seen in our HPV-negative patients may be due to a favorable biologic influence of an intact p16 INK4a protein expression. This analysis demonstrated a high concordance between p16 INK4a and HPV status and suggests that our TORS approach may possibly be improving the outcome of HPV-negative p16 INK4a -negative patients. Only 6% of our study patients were HPV negative/ p16 INK4a positive. The favorable prognosis associated with HPV oncogenesis for oropharyngeal carcinomas is now well recognized. 2,4,5,14 Although the biologic explanation for this is unclear at this time, several reports have suggested that this may be due to an increased radiosensitivity associated with HPV oncogenesis. 15,16 Gupta et al. demonstrated a significant difference in clonogenic radiosensitivities between two HPV-16 naturally infected head and neck cell lines compared to the HPVnegative SQ-20B head and neck cell line. 16 The degree of sensitivity correlated with the activation of the downstream Akt protein, and further radiosensitization could be achieved with Akt inhibition with the HIV protease inhibitor, nelfinavir. 16 Other potential mechanisms, including the influence of the tumor microenvironment on tumor radiosensitivity, have also been suggested. It is important to note that there are clear limitations in attributing a biologic explanation to the lack of prognostic impact of p16 INK4a on survival in our study population. The most relevant is the influence of selection bias that can occur with any institutional clinical series with a modest study population size and the low event rate that has been observed to date despite a median follow-up of 38.8 months. The findings reported should be more appropriately regarded as hypothesis generating and require further validation. With this in mind, several recent investigations provide a framework on which future investigations may be directed to improve the understanding of how p16 INK4a may be influencing the prognosis of OPSCC. Recent investigations suggest that tumor hypoxia may be more clinically important in the radiosensitivity of p16 INK4a - negative HNSCC cells based on the retrospective analysis of two large randomized trials that studied the oncologic outcome of hypoxic radiosensitization. 17,18 In the Danish Head and Neck Cancer Group (DAHANCA) 5 trial, Lassen et al. demonstrated that only in the p16 INK4a -negative cohort was there a statistically significant difference in LRC rates between patients randomized to radiotherapy and those receiving radiotherapy, and the concurrent hypoxic radiosensitizer nimorazole (5-year LRC, 20% vs. 37% respectively; 95% confidence interval [CI], ). 17 In the p16 INK4a - positive cohort, the 5-year LRC rate was almost identical (59% with nimorazole, 58% in the control group [hazard ratio (HR) ¼ 0.93; 95% CI, ]). In the Trans-Tasman Radiation Oncology Group (TROG) trial, Rischin et al. demonstrated a trend favoring the tirapazamine, cisplatin, and radiotherapy arm compared to the cisplatin and radiotherapy arm for improved localregional disease control only in the p16 INK4a -negative patients (HR ¼ 0.33; 95% CI, ; P ¼.13). The high LRC rates observed in our study population (Fig. 1) may be consistent with the hypothesis that surgical resection may be more effective in p16 INK4a - negative OPSCC. However, we note that only one localregional event occurred in each of the p16 INK4a -positive and p16 INK4a -negative cohorts, and thus may be influenced by the relatively modest size of the study population. In the p16 INK4a -negative OPSCC group, no local relapses have been observed to date. If p16 INK4a is influencing its prognostic significance through its relationship with the tumor oxygenation status, one might speculate that the impact of surgery on its prognostic significance may possibly be related to the burden of any residual microscopic disease requiring postoperative radiotherapy. In contrast, p16 INK4a -negative patients treated definitively with radiotherapy alone may show a more consistent detrimental prognostic effect. Table IV summarizes the studies that have reported on the prognostic impact of p16 INK4a protein immunohistochemistry (IHC). The most noteworthy observation is a consistent prognostic influence of p16 INK4a IHC in reports that have treated HNSCC with fractionated radiotherapy. Table IV also demonstrates that the adverse prognosis occurred despite the use of variable monoclonal antibodies and definitions for a positive p16 INK4a tumor. To date, no other TORS series has analyzed the impact of HPV or p16 INK4a IHC on the outcome of an upfront TORS approach. However, Rich et al. did analyze their results using a transoral laser microsurgical approach, which serially resects portions of the oropharyngeal tumor until a tumor normal-tissue interface appears to have been reached. Thus, the confidence one may have in the margin status after a complete surgical resection can be limited. The study population analyzed by Klussman et al. noted a positive margin rate of 11%. 19 The positive margin rate was not reported in the series by Fischer et al. 20 or the proportion of patients needing postoperative radiotherapy. CONCLUSION The results reported suggest that p16 INK4a may not have a significant influence on the survival rates of oropharyngeal carcinomas treated with an upfront TORS approach. Further validation of these results is required. Further evaluation of the potential relationship between tumor hypoxia and p16 INK4a oropharyngeal carcinomas are also warranted to determine if TORS may offer potential therapeutic advantages in 16 INK4a -negative oropharyngeal carcinomas. BIBLIOGRAPHY 1. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:
6 2. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100: Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. Effect of HPV-associated p16ink4a expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009;27: Settle K, Posner MR, Schumaker LM, et al. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila) 2009;2: Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006;24: Smith EM, Pawlita M, Rubenstein LM, Haugen TH, Hamsikova E, Turek LP. Risk factors and survival by HPV-16 E6 and E7 antibody status in human papillomavirus positive head and neck cancer. Int J Cancer 2010;127: Cohen MA, Weinstein GS, O Malley BW Jr, Feldman M, Quon H. Transoral robotic surgery (TORS) and human papillomavirus (HPV) status: oncologic results. Head Neck 2011;33: Overgaard J, Hansen HS, Overgaard M, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol Radiother Oncol 1998;46: Weinstein GS, O Malley BW Jr, Cohen MA, Quon H. Transoral robotic surgery (TORS) for advanced oropharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 2010;136: O Malley BW Jr, Weinstein GS, Snyder W, Hockstein NG. Transoral robotic surgery (TORS) for base of tongue neoplasms. Laryngoscope 2006;116: Weinstein GS, O Malley BW Jr, Snyder W, Sherman E, Quon H. Transoral robotic surgery: radical tonsillectomy. Arch Otolaryngol Head Neck Surg 2007;133: Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(ink4a) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92: Obiso R, Lorincz A. Digene Corporation. Pharmacogenomics 2004;5: Worden FP, Hooton J, Lee J, et al. Association of tobacco (T) use with risk of distant metastases (DM), tumor recurrence, and death in patients (pts) with HPV-positive (þ) squamous cell cancer of the oropharynx (SCCOP) [meeting abstract]. J Clin Oncol 2009;27: Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 2001;92: Gupta AK, Lee JH, Wilke WW, et al. Radiation response in two HPVinfected head-and-neck cancer cell lines in comparison to a non-hpvinfected cell line and relationship to signaling through AKT. Int J Radiat Oncol Biol Phys 2009;74: Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol 2010;94: Rischin D,Young R, Fisher R, et al. Prognostic significance of HPV and p16 status in patients with oropharyngeal cancer treated on a large international phase III trial [meeting abstract]. J Clin Oncol 2010;28: Klussmann JP, Gultekin E, Weissenborn SJ, et al. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 2003;162: Fischer CA, Zlobec I, Green E, et al. Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality? Int J Cancer 2009;126: Rich JT, et al. Transoral laser microsurgery (TLM) 6 adjuvant therapy for advanced stage oropharyngeal cancer: outcomes and prognostic factors. Laryngoscope 2009;119: Kumar B, et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008;26: Higuchi E, et al. Prognostic significance of cyclin D1 and p16 in patients with intermediate-risk head and neck squamous cell carcinoma treated with docetaxel and concurrent radiotherapy. Head Neck 2007;29: Shi W, et al. Comparative prognostic value of HPV16 E6 mrna compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 2009;27: Li W, et al. Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. Int J Cancer 2003;106:
HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium
HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium DISCLOSURE OF INTEREST Nothing to declare HEAD AND NECK CANCER -HPV
More informationJ Clin Oncol 27: by American Society of Clinical Oncology INTRODUCTION
VOLUME 27 NUMBER 12 APRIL 09 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Effect of HPV-Associated p16 INK4A Expression on Response to Radiotherapy and Survival in Squamous Cell Carcinoma of
More informationDe-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
More informationPrevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer
ORIGINAL ARTICLE Prevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer Shamir P. Chandarana, MD, MSc, 1 Julia S. Lee, MS,
More informationClinical Trials in Transoral Endoscopic Head &Neck Surgery ECOG3311 and RTOG1221. Chris Holsinger, MD, FACS Bob Ferris, MD, PhD, FACS
Clinical Trials in Transoral Endoscopic Head &Neck Surgery ECOG3311 and RTOG1221 Chris Holsinger, MD, FACS Bob Ferris, MD, PhD, FACS 1 Disclosure I have no conflicts of interest to disclose 2 Robotic H&N
More informationQuality of Life in Head and Neck Cancer Patients: Impact of HPV and Primary Treatment Modality
The Laryngoscope VC 2013 The American Laryngological, Rhinological and Otological Society, Inc. Quality of Life in Head and Neck Cancer Patients: Impact of HPV and Primary Treatment Modality Jessica H.
More informationAccepted 28 April 2005 Published online 13 September 2005 in Wiley InterScience ( DOI: /hed.
DEFINING RISK LEVELS IN LOCALLY ADVANCED HEAD AND NECK CANCERS: A COMPARATIVE ANALYSIS OF CONCURRENT POSTOPERATIVE RADIATION PLUS CHEMOTHERAPY TRIALS OF THE EORTC (#22931) AND RTOG (#9501) Jacques Bernier,
More informationPre- Versus Post-operative Radiotherapy
Postoperative Radiation and Chemoradiation: Indications and Optimization of Practice Dislosures Clinical trial support from Genentech Inc. Sue S. Yom, MD, PhD Associate Professor UCSF Radiation Oncology
More informationHead and Neck SCC. HPV in Tumors of the Head and Neck. Overview. Role of HPV in Pathogenesis of Head & Neck Tumors
HPV in Tumors of the Head and Neck Christina Kong, M.D. Associate Professor, Stanford Dept of Pathology Director, Cytopathology Laboratory & Cytopathology Fellowship ckong@stanford.edu Head and Neck SCC
More informationORIGINAL ARTICLE. Transoral Robotic-Assisted Surgery for Head and Neck Squamous Cell Carcinoma
ORIGINAL ARTICLE Transoral Robotic-Assisted Surgery for Head and Neck Squamous Cell Carcinoma One- and 2-Year Survival Analysis Hilliary N. White, MD; Eric J. Moore, MD; Eben L. Rosenthal, MD; William
More informationHPV and Head and Neck Cancer: What it means for you and your patients
HPV and Head and Neck Cancer: What it means for you and your patients Financial Disclosure: None November 8, 2013 Steven J. Wang, MD Associate Professor Department of Otolaryngology-Head and Neck Surgery
More informationThomas Gernon, MD Otolaryngology THE EVOLVING TREATMENT OF SCCA OF THE OROPHARYNX
Thomas Gernon, MD Otolaryngology THE EVOLVING TREATMENT OF SCCA OF THE OROPHARYNX Disclosures I have nothing to disclose. 3 Changing Role of Surgery N=42,688 Chen Ay et al. Larygoscope. 2007; 117:16-21
More informationHead and Neck Cancer in FA: Risks, Prevention, Screening, & Treatment Options David I. Kutler, M.D., F.A.C.S.
Head and Neck Cancer in FA: Risks, Prevention, Screening, & Treatment Options David I. Kutler, M.D., F.A.C.S. Associate Professor Division of Head and Neck Surgery Department of Otolaryngology-Head and
More informationCase Report Concurrent Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx in a Married Couple
Case Reports in Otolaryngology Volume 2016, Article ID 8481235, 4 pages http://dx.doi.org/10.1155/2016/8481235 Case Report Concurrent Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
More informationSurgical Margins in Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma
Surgical Margins in Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma Consensus update and recommendations, 2018 Head and Neck Steering Committee P. Gorphe *, F. Nguyen, Y. Tao, P. Blanchard,
More informationHuman Papillomavirus and Head and Neck Cancer. Ed Stelow, MD
Human Papillomavirus and Head and Neck Cancer Ed Stelow, MD No conflict of interest Declaration Cancer 1974 Lancet Oncol 2016; 17: e477-8 JAMA 1984; 252: 1857 JAMA 1988;259(13):1943-1944 Clin Cancer Res
More informationLaryngeal Preservation Using Radiation Therapy. Chemotherapy and Organ Preservation
1 Laryngeal Preservation Using Radiation Therapy 1903: Schepegrell was the first to perform radiation therapy for the treatment of laryngeal cancer Conventional external beam radiation produced disappointing
More informationHuman Papillomavirus Testing in Head and Neck Carcinomas
Human Papillomavirus Testing in Head and Neck Carcinomas Guideline from the College of American Pathologists Early Online Release Publication: Archives of Pathology & Laboratory Medicine 12/18/2017 Overview
More informationUpdate on Oral HPV Service and Related Research K Cuschieri, presented at Shine Meeting 25/09/12.
Update on Oral HPV Service and Related Research K Cuschieri, presented at Shine Meeting 25/09/12. Non Cervical Cancers with an HPV aetiology 1. Anal 2. Penile 3. Vulval 4. Vaginal 5. Component of head
More informationTransoral Robotic Surgery (TORS) for Oropharyngeal Cancer
Transoral Robotic Surgery (TORS) for Oropharyngeal Cancer Ellie Maghami, MD, FACS Professor of Otolaryngology / Head and Neck Surgery Chief, Division of Head and Neck Surgery Norman and Sadie Lee Professor
More informationHead and Neck Cancer:
Head and Neck Cancer: Robert Haddad M.D. Clinical Director Head and Neck Oncology Program Dana Farber Cancer Institute Boston, MA Predictive Biomarkers: HPV Abstract 6003: Survival Outcomes By HPV Status
More informationLymph node density as an independent prognostic factor in node-positive patients with tonsillar cancer
ORIGINAL ARTICLE Lymph node density as an independent prognostic factor in node-positive patients with tonsillar cancer Jun-Ook Park, MD, PhD, 1 Young-Hoon Joo, MD, PhD, 2 Kwang-Jae Cho, MD, PhD, 2 Min-Sik
More informationTable of Contents. 1. Overview. 2. Interpretation Guide. 3. Staining Gallery Cases Negative for CINtec PLUS
Staining Atlas Table of Contents 1. Overview 1.1 Introduction 1.2 Role of p16 INK4a 1.3 Role of Ki-67 1.4 Molecular Pathogenesis 1.5 p16 INK4a Expression in Cervical Dysplasia 1.6 The Concept of CINtec
More informationP16 INK4A EXPRESSION AS A POTENTIAL PROGNOSTIC MARKER IN CERVICAL PRECANCEROUS AND CANCEROUS LESIONS IN MOROCCO
P16 INK4A EXPRESSION AS A POTENTIAL PROGNOSTIC MARKER IN CERVICAL PRECANCEROUS AND CANCEROUS LESIONS IN MOROCCO Yassine Zouheir Laboratory of histo-cytopathology of Institut Pasteur of Morocco, Casablanca,
More informationAdjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support
Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no
More informationSelf-Assessment Module 2016 Annual Refresher Course
LS16031305 The Management of s With r. Lin Learning Objectives: 1. To understand the changing demographics of oropharynx cancer, and the impact of human papillomavirus on overall survival and the patterns
More informationHuman Papillomavirus and Survival of Patients with Oropharyngeal Cancer
The new england journal of medicine original article Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer K. Kian Ang, M.D., Ph.D., Jonathan Harris, M.S., Richard Wheeler, M.D., Randal
More informationHIGH-RISK HPV DNA STATUS AND P16(INK4A) EXPRESSION
POL J PATHOL 2010; 3: 133 139 HIGH-RISK HPV DNA STATUS AND P16(INK4A) EXPRESSION AS PROGNOSTIC MARKERS IN PATIENTS WITH SQUAMOUS CELL CANCER OF ORAL CAVITY AND OROPHARYNX MIROSŁAW ŚNIETURA 1, MAGDALENA
More informationTriple-Modality Treatment in Patients With Advanced Stage Tonsil Cancer
Triple-Modality Treatment in Patients With Advanced Stage Tonsil Cancer Dylan F. Roden, MD, MPH 1,2 ; David Schreiber, MD 2,3 ; and Babak Givi, MD 1,2 BACKGROUND: Concurrent chemoradiation (CCRT) and upfront
More informationHuman Papillomavirus and Survival of Patients with Oropharyngeal Cancer
The new england journal of medicine original article Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer K. Kian Ang, M.D., Ph.D., Jonathan Harris, M.S., Richard Wheeler, M.D., Randal
More informationLocally advanced head and neck cancer
Locally advanced head and neck cancer Radiation Oncology Perspective Petek Erpolat, MD Gazi University, Turkey Definition and Management of LAHNC Stage III or IV cancers generally include larger primary
More informationHumaan Papillomavirus en hoofd/halskanker. Pol Specenier
Humaan Papillomavirus en hoofd/halskanker Pol Specenier pol.specenier@uza.be Humaan Papillomavirus en hoofd/halskanker Hoofd/halskanker: incidentie en oorzaken Oropharynx carcinoom Incidentie HPV HPV en
More informationService Line: Rapid Response Service Version: 1.0 Publication Date: Month XX, 2017 Report Length: 79 Pages
CADTH RAPID RESPONSE REPORT: SYSTEMATIC REVIEW Treatments for Locally Advanced Oropharyngeal Cancer: A Systematic Review of Clinical Effectiveness and Cost- Effectiveness Service Line: Rapid Response Service
More informationOriginal Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical outcome
Int J Clin Exp Pathol 2017;10(2):2030-2035 www.ijcep.com /ISSN:1936-2625/IJCEP0009456 Original Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical
More informationCirculating invariant natural killer T-cell numbers predict outcome in head and neck squamous cell carcinoma: Updated analysis with 10-year follow-up
Chapter Circulating invariant natural killer T-cell numbers predict outcome in head and neck squamous cell carcinoma: Updated analysis with 10-year follow-up Famke L. Schneiders, Renée C.G. de Bruin, Fons
More informationDisclosure. Access 10/4/2013. The emerging role of TransOralRobotic Surgery (TORS) Organ preservation in the management of head and neck cancer
Disclosure The emerging role of TransOralRobotic Surgery (TORS) Intuitive Surgical, Inc. Proctor/Honoraria Eddie Méndez, MD, MS, FACS Associate Professor, Department of Otolaryngology: Head & Neck Surgery
More informationMANAGEMENT OF LOCALLY ADVANCED OROPHARYNGEAL CANER: HPV AND NON-HPV MEDIATED CANCERS
MANAGEMENT OF LOCALLY ADVANCED OROPHARYNGEAL CANER: HPV AND NON-HPV MEDIATED CANCERS Kyle Arneson, MD PhD Avera Medical Group Radiation Oncology Avera Cancer Institute 16 th Annual Oncology Symposium September
More informationGreater Baltimore Medical Center Sandra & Malcolm Berman Cancer Institute
2008 ANNUAL REPORT Greater Baltimore Medical Center Sandra & Malcolm Berman Cancer Institute Cancer Registry Report The Cancer Data Management System/ Cancer Registry collects data on all types of cancer
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides
More informationp16 Expression in cutaneous squamous carcinomas with neck metastases: A potential pitfall in identifying unknown primaries of the head and neck
ORIGINAL ARTICLE p16 Expression in cutaneous squamous carcinomas with neck metastases: A potential pitfall in identifying unknown primaries of the head and neck Beth M. Beadle, MD, PhD, 1 William N. William,
More informationA Systematic Review of Transoral Robotic Surgery and Radiotherapy for Early Oropharynx Cancer: A Systematic Review
The Laryngoscope VC 2014 The American Laryngological, Rhinological and Otological Society, Inc. Systematic Review A Systematic Review of Transoral Robotic Surgery and Radiotherapy for Early Oropharynx
More informationEvaluation and Management of Head and Neck Cancer in Patients with Fanconi anemia David I. Kutler, M.D., F.A.C.S.
Evaluation and Management of Head and Neck Cancer in Patients with Fanconi anemia David I. Kutler, M.D., F.A.C.S. Residency Site Director Weill Cornell Medical Center Associate Professor Division of Head
More informationPredictive Accuracy of First Post-Treatment PET/CT in HPV-Related Oropharyngeal Squamous Cell Carcinoma
The Laryngoscope VC 2014 The American Laryngological, Rhinological and Otological Society, Inc. Predictive Accuracy of First Post-Treatment in HPV-Related Oropharyngeal Squamous Cell Carcinoma Yekaterina
More informationHPV-Related Head and Neck Squamous Cancers
2015 Wisconsin Comprehensive Cancer Control Summit Aligning Partners, Priorities, and the Plan HPV-Related Head and Neck Squamous Cancers MCW Department of Otolaryngology and Communication Sciences MCW
More informationHPV Analysis of Head and Neck Squamous Cell Carcinomas based on Fine-Needle. Aspiration Specimens. William H. Westra M.D.
HPV Analysis of Head and Neck Squamous Cell Carcinomas based on Fine-Needle Aspiration Specimens William H. Westra M.D. The Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore Maryland
More informationHPV POSITIVE OROPHARYNGEAL CARCINOMA the radiation oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium
HPV POSITIVE OROPHARYNGEAL CARCINOMA the radiation oncologist point of view Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium HEAD AND NECK CANCER -HPV Change in incidence: HEAD AND NECK
More informationEFFICACY OF NECK DISSECTION FOR LOCOREGIONAL FAILURES VERSUS ISOLATED NODAL FAILURES IN NASOPHARYNGEAL CARCINOMA
ORIGINAL ARTICLE EFFICACY OF NECK DISSECTION FOR LOCOREGIONAL FAILURES VERSUS ISOLATED NODAL FAILURES IN NASOPHARYNGEAL CARCINOMA Raymond King Yin Tsang, FRCSEd, Joseph Chun Kit Chung, MRCSEd, Yiu Wing
More informationOutcomes in Oncology
Outcomes in Oncology Ochsner Cancer Institute s Report to Physicians May 2014 ochsner.org/cancer Head and Neck Cancer Update: New Strategies for the Treatment of Oropharyngeal Cancer Dear Physicians, In
More informationNew Paradigms for Treatment of. Erminia Massarelli, MD, PHD, MS Clinical Associate Professor
New Paradigms for Treatment of Head and Neck cancers Erminia Massarelli, MD, PHD, MS Clinical Associate Professor City of Hope Disclosure Statement Grant/Research Support frommerck Bristol Grant/Research
More informationPatterns of nodal metastasis and prognosis in human papillomavirus positive oropharyngeal squamous cell carcinoma
ORIGINAL ARTICLE Patterns of nodal metastasis and prognosis in human papillomavirus positive oropharyngeal squamous cell carcinoma Matthew E. Spector, MD, 1 K. Kelly Gallagher, MD, 1 Emily Bellile, MS,
More informationSimultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer
Simultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer Dawn Gintz, CMD, RTT Dosimetry Coordinator of Research and
More informationThe management of advanced supraglottic and
ORIGINAL ARTICLE ORGAN PRESERVATION FOR ADVANCED LARYNGEAL CARCINOMA Robert L. Foote, MD, 1 R. Tyler Foote, 1 Paul D. Brown, MD, 1 Yolanda I. Garces, MD, 1 Scott H. Okuno, MD, 2 Scott E. Strome, MD 3 1
More informationThe Changing Face of Head and Neck Cancer in the 21st Century: The Impact of HPV on the Epidemiology and Pathology of Oral Cancer. William H.
The Changing Face of Head and Neck Cancer in the 21st Century: The Impact of HPV on the Epidemiology and Pathology of Oral Cancer William H. Westra From the Department of Pathology and Otolaryngology/Head
More informationThe effect of delayed adjuvant chemotherapy on relapse of triplenegative
Original Article The effect of delayed adjuvant chemotherapy on relapse of triplenegative breast cancer Shuang Li 1#, Ding Ma 2#, Hao-Hong Shi 3#, Ke-Da Yu 2, Qiang Zhang 1 1 Department of Breast Surgery,
More information1. Introduction. 2. Materials and methods. Volume 6 Issue 8, August 2017
Over Expression of p16 in Squamous Cell Carcinoma of the Oral Cavity Faiçal Slimani 1, Ouail ilhami 2, Hicham Elattar 3, Latifa Badre 4, Touria Aboussaouira 5 1 Stomatology and Maxillofacial Surgery Department
More informationORIGINAL ARTICLE. Predicting the Prognosis of Oral Squamous Cell Carcinoma After First Recurrence
ORIGINAL ARTICLE Predicting the Prognosis of Oral Squamous Cell Carcinoma After First Recurrence Michael D. Kernohan, FDSRCS, FRCS, MSc; Jonathan R. Clark, FRACS; Kan Gao, BEng; Ardalan Ebrahimi, FRACS;
More informationClinical analysis of 29 cases of nasal mucosal malignant melanoma
1166 Clinical analysis of 29 cases of nasal mucosal malignant melanoma HUANXIN YU and GANG LIU Department of Otorhinolaryngology Head and Neck Surgery, Tianjin Huanhu Hospital, Tianjin 300060, P.R. China
More informationNICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng36
Cancer of the upper aerodigestive e tract: assessment and management in people aged 16 and over NICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng36 NICE 2018. All rights reserved. Subject
More informationPost-Operative Concurrent Chemoradiation with Mitomycin-C for Advanced Head and Neck Cancer
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 2006 Post-Operative Concurrent Chemoradiation with Mitomycin-C for
More informationNICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng36
Cancer of the upper aerodigestive e tract: assessment and management in people aged 16 and over NICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng36 NICE 2018. All rights reserved. Subject
More informationMANAGEMENT OF CA HYPOPHARYNX
MANAGEMENT OF CA HYPOPHARYNX GENERAL TREATMENT RECOMMENDATIONS BASED ON HYPOPHARYNX TUMOR STAGE For patients presenting with early-stage definitive radiotherapy alone or voice-preserving surgery are viable
More information1. Comprehensive assessment of prognostic markers for sinonasal squamous cell carcinoma
1 P a g e 1 1. Comprehensive assessment of prognostic markers for sinonasal squamous cell carcinoma Department of Head and Neck Surgery, Unit 123 The University of Texas MD Anderson Cancer Center, 1515
More informationProtocol of Radiotherapy for Head and Neck Cancer
106 年 12 月修訂 Protocol of Radiotherapy for Head and Neck Cancer Indication of radiotherapy Indication of definitive radiotherapy with or without chemotherapy (1) Resectable, but medically unfit, or high
More informationThe International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology
The International Federation of Head and Neck Oncologic Societies Current Concepts in Head and Neck Surgery and Oncology www.ifhnos.net The International Federation of Head and Neck Oncologic Societies
More informationESMO Perceptorship H&N cancer Epidemiology, Anatomy and Workup 16 March 2018
ESMO Perceptorship H&N cancer Epidemiology, Anatomy and Workup 16 March 2018 Dr. Victor Ho-Fun Lee MBBS, MD, FRCR, FHKCR, FHKAM (Radiology) Clinical Associate Professor Department of Clinical Oncology
More informationFirst of all, the pathophysiology
Welcome. My name is Eric Sturgis and I m a Professor in Head and Neck Surgery with a joint appointment in the Department of Epidemiology at The University of Texas MD Anderson Cancer Center. And today
More informationPiero Nicolai SURGERY FOR THE TREATMENT OF OROPHARYNGEAL CARCINOMA: STATE OF ART. Department of Otorhinolaryngology University of Brescia
Biology and technology contribution to clinical advancement: the case of oropharyngeal cancer Brescia May 8 th, 2009 SURGERY FOR THE TREATMENT OF OROPHARYNGEAL CARCINOMA: STATE OF ART Piero Nicolai Department
More informationSQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY IN THE ELDERLY
ORIGINAL ARTICLE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY IN THE ELDERLY Yi-Shing Leu 1,2,3 *, Yi-Fang Chang 4, Jehn-Chuan Lee 1, Chung-Ji Liu 2,5,6, Hung-Tao Hsiao 7, Yu-Jen Chen 8, Hong-Wen Chen 8,9,
More informationHead and Neck Reirradiation: Perils and Practice
Head and Neck Reirradiation: Perils and Practice David J. Sher, MD, MPH Department of Radiation Oncology Dana-Farber Cancer Institute/ Brigham and Women s Hospital Conflicts of Interest No conflicts of
More informationSurvival impact of cervical metastasis in squamous cell carcinoma of hard palate
Vol. 116 No. 1 July 2013 Survival impact of cervical metastasis in squamous cell carcinoma of hard palate Quan Li, MD, a Di Wu, MD, b,c Wei-Wei Liu, MD, PhD, b,c Hao Li, MD, PhD, b,c Wei-Guo Liao, MD,
More informationFINE NEEDLE ASPIRATION OF ENLARGED LYMPH NODE: Metastatic squamous cell carcinoma
Case Scenario 1 HNP: A 70 year old white male presents with dysphagia. The patient is a current smoker, current user of alcohol and is HPV positive. A CT of the Neck showed mass in the left pyriform sinus.
More informationIndications and techniques of surgery for the primary treatment of HNSCC
Prof. Christian Simon Chef-de-service Service d ORL et chirurgie cervico-faciale Centre Hospitalier Universitaire Vaudois (CHUV) Université de Lausanne Lausanne, Suisse Indications and techniques of surgery
More informationNews Briefing: Thursday, Feb. 20, 7 a.m. MT
News Briefing: Thursday, Feb. 20, 7 a.m. MT Moderator: David aben, MD, ymposium Chair and professor of radiation oncology, University of Colorado Cancer Center, Denver Domiciliary Humidification educes
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationCase Scenario. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised.
Case Scenario 7/5/12 History A 51 year old white female presents with a sore area on the floor of her mouth. She claims the area has been sore for several months. She is a current smoker and user of alcohol.
More informationORIGINAL ARTICLE. Salvage Surgery After Failure of Nonsurgical Therapy for Carcinoma of the Larynx and Hypopharynx
ORIGINAL ARTICLE Salvage Surgery After Failure of Nonsurgical Therapy for Carcinoma of the Larynx and Hypopharynx Sandro J. Stoeckli, MD; Andreas B. Pawlik, MD; Margareta Lipp, MD; Alexander Huber, MD;
More informationPoor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas
10 The Open Otorhinolaryngology Journal, 2011, 5, 10-14 Open Access Poor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas Kevin C. Huoh and Steven J. Wang * Head and Neck Surgery and Oncology,
More informationPersistent Tracheostomy after Organ Preservation Protocol in Patients Treated for Larynx and Hypopharynx Cancer
THIEME Original Research 377 Persistent Tracheostomy after Organ Preservation Protocol in Patients Treated for Larynx and Hypopharynx Cancer Carlos Miguel Chiesa Estomba Frank Alberto Betances Reinoso
More informationOral Cavity Cancer Combined modality therapy
Oral Cavity Cancer Combined modality therapy Dr. Christos CHRISTOPOULOS Radiation Oncologist Head and Neck Cancers Centre Hospitalier Universitaire (C.H.U.) de Limoges, France Disclosure slide I have no
More informationMetastatic Carcinoma to Percutaneous Endoscopic Gastrostomy Tube Sites. A Report of Five Cases
Metastatic Carcinoma to Percutaneous Endoscopic Gastrostomy Tube Sites A Report of Five Cases Lanjing Zhang, MD, MS, 1,2 Stephanie A. Dean, MD, 1 Emma E. Furth, MD, 1 Gregory S. Weinstein, MD, 3 Virginia
More informationThe efficacy of postoperative radiation therapy in patients with carcinoma of the buccal mucosa and lower alveolus with positive surgical margins
Original Article The efficacy of postoperative radiation therapy in patients with carcinoma of the buccal mucosa and lower alveolus with positive surgical margins Badakh Dinesh K, Grover Amit H Dr. D.
More informationCancer Research Group Version Date: November 5, 2015 NCI Update Date: January 15, Schema. L O Step 1 1,2
Cancer esearch roup ev. 6/14, 2/15, 1/16 Step 2 Schema 5 Arm A: (7 weeks) Step 1 1,2 N Accrual: 515 S Arm S ransoral esection dissections S A N D M Z 4 ntermediate isk 7 Stratify: = 10 pk-yr vs. > 10 pk-yr
More informationNasopharyngeal Cancer/Multimodality Treatment
Nasopharyngeal Cancer/Multimodality Treatment PANAGIOTIS KATSAOUNIS Medical Oncologist IASO GENERAL HOSPITAL Athens, 22/10/2016 1 st Hellenic Multidisciplinary Conference on Head and Neck Cancer INTRODUCTION
More informationCorrelation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer
Correlation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer X.L. Liu 1, L.D. Liu 2, S.G. Zhang 1, S.D. Dai 3, W.Y. Li 1 and L. Zhang 1 1 Thoracic Surgery,
More informationWHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER?
CANCER STAGING TNM and prognosis in CRC WHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER? Alessandro Lugli, MD Institute of Pathology University of Bern Switzerland Maastricht, June 19
More informationOutcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21 st century
Garden et al. Radiation Oncology 2013, 8:21 RESEARCH Open Access Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21 st century Adam S Garden
More informationHead and Neck Cancer Update Sandro V Porceddu
Head and Neck Cancer Update Sandro V Porceddu Director, Radiation Oncology Research Princess Alexandra Hospital, Brisbane Associate Professor, University of Queensland President, Trans Tasman Radiation
More informationRising prevalence of human papillomavirus related oropharyngeal cancer in Australia over the last 2 decades
ORIGINAL ARTICLE Rising prevalence of human papillomavirus related oropharyngeal cancer in Australia over the last 2 decades Angela Hong, PhD, 1,2 * C. Soon Lee, MD, 1,3 Deanna Jones, BAppSci, 4 Anne-Sophie
More informationHigh expression of fibroblast activation protein is an adverse prognosticator in gastric cancer.
Biomedical Research 2017; 28 (18): 7779-7783 ISSN 0970-938X www.biomedres.info High expression of fibroblast activation protein is an adverse prognosticator in gastric cancer. Hu Song 1, Qi-yu Liu 2, Zhi-wei
More informationCorrelation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW
Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW BACKGROUND AJCC staging 1 gives valuable prognostic information,
More informationReporting HPV related carcinomas of the head and neck. dr. Nina Zidar Institute of Pathology Faculty of Medicine University of Ljubljana Slovenia
Reporting HPV related carcinomas of the head and neck dr. Nina Zidar Institute of Pathology Faculty of Medicine University of Ljubljana Slovenia Conflict of interest/funding X None Company: Product royalties
More informationCase Scenario 1. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised.
Case Scenario 1 7/5/12 History A 51 year old white female presents with a sore area on the floor of her mouth. She claims the area has been sore for several months. She is a current smoker and user of
More informationThe Use of TORS for HPV-Related Oropharynx Cancer
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/the-use-of-tors-for-hpvrelated-oropharynx-cancer/7251/
More informationShould we still be performing IHC on all sentinel nodes?
Miami Breast Cancer Conference 31 st Annual Conference March 8, 2014 Should we still be performing IHC on all sentinel nodes? Donald L. Weaver, MD Professor of Pathology University of Vermont USA Miami
More informationCopyright information:
Clinical outcomes in elderly patients with human papillomavirus-positive squamous cell carcinoma of the oropharynx treated with definitive chemoradiation therapy Sheela Hanasoge, Emory University Kelly
More informationDRAFT FOR CONSULTATION. Clinical Commissioning Policy Proposition: Robotic assisted trans-oral surgery for throat and voice box cancers
Clinical Commissioning Policy Proposition: Robotic assisted trans-oral surgery for throat and voice box cancers Information Reader Box (IRB) to be inserted on inside front cover for documents of 6 pages
More informationClinical Discussion. Dr Pankaj Chaturvedi. Professor and Surgeon Tata Memorial Hospital
Clinical Discussion Dr Pankaj Chaturvedi Professor and Surgeon Tata Memorial Hospital chaturvedi.pankaj@gmail.com 47/M/smoker Hopkins : Transglottic lesion No cartilage infiltration but sclerosis Left
More informationHPV and Head and Neck Cancer
William C. Faquin, MD, PhD, FCAP Director, Head and Neck Pathology Massachusetts General Hospital Associate Professor of Pathology Harvard Medical School HPV and Head and Neck Cancer A number of testing
More informationRacial Survival Disparity in Head and Neck Cancer Results from Low Prevalence of Human Papillomavirus Infection in Black Oropharyngeal Cancer Patients
Published Online First on July 29, 2009 as 10.1158/1940-6207.CAPR-09-0149 Cancer Prevention Research Racial Survival Disparity in Head and Neck Cancer Results from Low Prevalence of Human Papillomavirus
More information